AURKA and diffuse large B-cell lymphoma: In CHOP group and siNC+CHOP group, there were no obvious changes in the expressions of AURKA and RAS as well as the ratios of p-β-Catenin/β-Catenin and p-ERK1/2/ERK1/2, implicating that silencing AURKA reinforced the therapeutic effects of CHOP on DLBCL via suppressing the β-Catenin pathway and RAS-ERK1/2 pathway.